Lautman Foundation
1
10M
1
0.08
1
- Areas of investment
Summary
Lautman Foundation appeared to be the VC, which was created in 2008.
The standard case for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Shmuel Kabili, Fischer Pharmaceutical Laboratories Ltd, Fidelity Ventures. In the next rounds fund is usually obtained by Yelin Lapidot Investment House, ROTH Capital Partners, OrbiMed.
The fund is constantly included in less than 2 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund. The important activity for fund was in 2010. The increased amount of exits for fund were in 2013.
The current fund was established by Noam Lautman.
Moreover, a startup needs to be at the age of 1 and less years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight RedHill Biopharma. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Biotechnology.
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 0
- Exits
- 1
- Rounds per year
- 0.08
- Investments by industry
- Drug Discovery (1)
- Pharmaceutical (1)
- Health Care (1)
- Biotechnology (1)
- Investments by region
-
- Israel (1)
- Peak activity year
- 2010
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.